Phase 2 NMIBC Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 2
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled42 locationsNCT06995677
Recruiting
Phase 2
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shanxi Province Cancer Hospital30 enrolled1 locationNCT07646145
Recruiting
Phase 2
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
Urothelial CarcinomaBladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)+8 more
Michael A. O'Donnell174 enrolled1 locationNCT07322263
Recruiting
Phase 1Phase 2
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NMIBC
ImmunityBio, Inc.40 enrolled9 locationsNCT06800963
Recruiting
Phase 2
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc.90 enrolled16 locationsNCT03945162
Recruiting
Phase 1Phase 2
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Suzhou Forlong Biotechnology Co., Ltd80 enrolled12 locationsNCT07122414
Recruiting
Phase 1Phase 2
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
High-risk NMIBC
Shanghai Hengrui Pharmaceutical Co., Ltd.150 enrolled1 locationNCT05410730
Recruiting
Phase 2
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
NMIBC
RemeGen Co., Ltd.85 enrolled1 locationNCT05943379